Aramchol, an investigational therapy for idiopathic pulmonary fibrosis (IPF), demonstrated significant anti-fibrotic effects in a mouse model. The therapy,…
Articles by Steve Bryson, PhD
Ofev (nintedanib), a medicine approved to treat progressive fibrosing interstitial lung disease (PF-ILD), now is available for public reimbursement…
Oral therapies that kill aging cells were found to boost the levels of alpha-Klotho, a protective protein that declines with…
An extract of the plant Lemna minor L., also called duckweed, suppresses the signs and symptoms of idiopathic pulmonary…
Lung Therapeutics’ LTI-03, an investigational inhaled therapy for idiopathic pulmonary fibrosis (IPF), was safe and well-tolerated in healthy…
Problems in the metabolism of low-density lipoprotein (LDL) — also known as “bad cholesterol” — and its receptor contribute to…
The investigational oral therapy Haduvio (nalbuphine extended-release tablets) significantly reduced chronic cough in people with idiopathic pulmonary fibrosis…
The U.S. Food and Drug Administration (FDA) has given breakthrough status to Boehringer Ingelheim’s BI-1015550, an experimental oral therapy…
The approved antibiotic nifuroxazide halted the development, and reversed the signs, of induced pulmonary fibrosis (PF) in mice, a…
An analysis of gene activity profiles in lung tissue has identified important drivers of idiopathic pulmonary fibrosis (IPF). The…